Why the study?
Does a losartan-based treatment regimen reduce carotid artery plaque development compared to an atenolol-based regimen in hypertensive patients with left ventricular hypertrophy?
Population
n=81 hypertensive patients with left ventricular hypertrophy
Comparison
Losartan-based treatment regimen for 3 years vs Atenolol-based treatment regimen for 3 years
Design
RCT
Follow-up
3 years
Authors
Loading...
Losartan shows no carotid plaque advantage over atenolol; extends LIFE evidence that outcome benefits occur via plaque-independent mechanisms.
Does a losartan-based treatment regimen reduce carotid artery plaque development compared to an atenolol-based regimen in hypertensive patients with left ventricular hypertrophy?
In a small substudy of the LIFE trial, losartan did not significantly reduce carotid plaque amount or density compared to atenolol over 3 years, though statistical power was limited.
Fossum et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: